Loading patent…
AssigneeAbraxis BioScience, LLC
InventorsNeil P. Desai, Patrick Soon-Shiong
Estimating the term…
The present invention relates to methods and kits for the treatment of breast cancer based on hormone receptor status of progesterone receptor and estrogen receptor comprising the administration of a taxane alone, in combination with at least one other and other therapeutic agents, as well as other treatment modalities useful in the treatment of breast cancer. In particular, the invention relates to the use of nanoparticles comprising paclitaxel and albumin (such as Abraxane®) either alone or in combination with other chemotherapeutic agents or radiation, which may be used for the treatment of breast cancer which does not express estrogen receptor and/or progesterone receptor.
A method for treating breast cancer in an individual, the method comprising:
A method for treating breast cancer in an individual, the method comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising a taxane and a carrier protein, wherein negative hormone receptor status of estrogen receptor (ER−), progesterone receptor (PR−), and human epidermal growth factor receptor-2 (HER2−) is used as a basis for selecting the individual to receive treatment.
A method of identifying an individual suitable for breast cancer treatment, the method comprising determining hormone receptor status of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2, wherein the individual is identified as suitable for breast cancer treatment with nanoparticles comprising a taxane and a carrier protein if hormone receptor status is negative for estrogen receptor (ER−), progesterone receptor (PR−), and human epidermal growth factor receptor-2 (HER2−).
Dependencies are inferred from the claim text.